Richard Morris
About Richard Morris
Richard Morris is an experienced financial executive who has served as CFO for several biopharmaceutical companies, including Passage Bio and Vitae Pharmaceuticals.
Richard Morris Chief Financial Officer Background
Richard Morris has served as a high-ranking financial executive in multiple biopharmaceutical companies. Most recently, he was the Chief Financial Officer of Passage Bio, Inc. from October 2019 to May 2021. Prior to that, he held the role of Executive Vice President and Chief Financial Officer at Context Therapeutics. His extensive experience in the industry is further highlighted by his tenure as CFO for Vitae Pharmaceuticals, a company that was acquired by Allergan in 2016.
Richard Morris Education and Expertise
Richard Morris holds a Bachelor of Science degree in Accounting from Saint Joseph's University. His expertise is reinforced by his status as a certified public accountant. This solid educational background is complemented by his extensive experience in financial management roles within the biopharmaceutical sector.
Richard Morris Vitae Pharmaceuticals Acquisition by Allergan
While serving as Chief Financial Officer at Vitae Pharmaceuticals, Richard Morris played a key role during the company’s acquisition by Allergan in 2016. His leadership in the financial domain was instrumental in guiding the company through this significant corporate transaction.
Richard Morris ViroPharma Tenure
Prior to his roles at Vitae Pharmaceuticals and Context Therapeutics, Richard Morris held several senior financial positions at ViroPharma. His tenure there included critical financial oversight during a period that culminated in the company's acquisition by Shire in 2013. His role at ViroPharma provided him with valuable experience in handling high-stakes financial operations in the biopharmaceutical industry.